SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a top trending stock as the community discusses its oral obesity drug VK2735 advancing directly to Phase 3, a move expected to accelerate its market entry and enhance its competitive stance in the rapidly expanding GLP-1 sector, especially with recent favorable regulatory developments against compounded alternatives.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape's recent earnings call disappointed some investors with a lack of specific commercialization timelines and production yields, triggering an after-hours stock drop. However, the company's newly operational Eagle Line pilot facility is now shipping B-samples to multiple OEMs, with apparent involvement from Nissan and Hitachi, sparking bullish hopes for scalable solid-state battery production and future licensing deals.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

NovoCure is trending following U.S. FDA approval of Optune Pax for locally advanced pancreatic cancer, hailed by the community as the first significant new treatment for this aggressive disease in decades. This breakthrough, supported by positive Phase 3 trial data, is fueling intense speculation of a massive short squeeze and substantial future growth, despite some cautionary perspectives on past stock volatility.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trending following a strong earnings report that delivered record revenue, gross margin, and operating profit, with bullish 2026 guidance driven by significant security growth and emerging AI tailwinds. The community is buzzing with anticipation for further upside and short covering, marking a potential turnaround despite some long-term investors advising caution on volatility.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is trending amid a sharp sell-off driven by concerns that T-Mobile's new AI translation service and the broader AI narrative could render language learning apps obsolete. The community is polarized, with bears dismissing its value, while bulls highlight strong user and revenue growth as proof that AI won't replace dedicated language learning and see a significant buying opportunity.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

The FDA's refusal to review Moderna's mRNA flu vaccine application is driving significant discussion, with many in the community believing this creates a major advantage for Novavax's correctly designed protein-based flu and COVID-flu combination trials. This development, coupled with notable institutional buying, intensifies calls for strategic partnerships or a company buyout to realize the stock's potential value.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is trending after reporting a Q1 earnings beat and raising its full-year guidance, largely driven by strong AI infrastructure orders. The community is actively discussing its pivotal role in the AI buildout and the notable historical context of its stock price approaching dot-com era highs.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X is trending due to its imminent merger with Infleqtion, a quantum technology leader landing a NASA space mission and a DOE energy grid contract, prompting community discussion about its undervalued status compared to peers. Investors are actively debating potential post-merger upside and low-float dynamics ahead of its NYSE relisting as INFQ.

Porch Group, Inc. engages in the development and operation of a vertical software platform. It operates through Vertical Software and Insurance segments. The Vertical Software segment provides software and services to home services companies, such as home inspectors, mortgage companies and loan officers, title companies, moving companies, real estate agencies, utility companies, and others. The Insurance segment operates both as an insurance carrier underwriting home insurance policies, and as agent selling home and auto insurance and also includes porch's warranty service offering. The company was founded by Matt Ehrlichman & Ronnie Castro in 2011 and is headquartered in Seattle, WA.

Porch Group Inc - Ordinary Shares - Class A

Porch Group is seeing a surge in conversation and trading volume after its strong earnings report highlighted improved profitability and significant cash flow from its reciprocal insurance model, fueling positive analyst upgrades and community optimism about its long-term prospects.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management system, as well as other tools, integrations and native payment solutions. It operates through the following geographical segments: Americas, Europe and Asia Pacific. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot is actively discussed following its Q4 earnings report, which showed strong performance and a $1 billion share repurchase program, yet the stock saw a sharp decline, fueling a community divide between those highlighting its value and others fearing "Death By AI" disruption across the software sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In this photo illustration, the Tempest Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction

The transaction is expected to close in early 2026, provided it receives all required approvals. 

Equity

The transaction is expected to close in early 2026, provided it receives all required approvals. 


Why Tempest Therapeutics (TPST) Stock Is Down 45% Today

Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience.read more...

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

Shares of Tempest Therapeutics (TPST) ended higher on Wednesday amid a broader market rebound on the U.S. pausing tariffs and extended gains after-hours after the company said it was exploring strategic alternatives.&nbsp;The cancer drug developer said its options included a merger, acquisition, partnership, or licensing deal to advance its pipeline and maximize shareholder value.&nbsp;The company has retained MTS Health Partners to assist with the process.CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat showing a six-month survival benefit in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.&nbsp;However, Brady said capital markets "have been unavailable to support the next stage of advancement."On Stocktwits, sentiment for Tempest surged into the 'extremely bullish' zone from 'neutral' a day ago, accompanied by message volume soaring over 135% in the 24 hours to late Wednesday.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/TPST_sentiment_and_message_volume_April_9_png_4939200400.webp" alt="TPST sentiment and message volume April 9.png" width="1318" height="316"><figcaption>TPST sentiment and message volume April 9. | source: Stocktwits</figcaption></figure>One user said the CEO was "soliciting bidders" through this move following the recent 1-for-13 reverse stock split."Poison pill is still at $25. Now, anyone who wants more than a 10 percent ownership stake can buy whatever they want at $25 or more. Well played, Mr. Brady!" they wrote.<stembedurl>https://stocktwits.com/xyz1232/message/611152790</stembedurl>Another pinned hopes on "well-known" MTS Partners fetching a good merger deal for Tempest. "Even If TPST gets a below-average deal at $360 million, we're still looking at $100 per share."<stembedurl>https://stocktwits.com/GreylockSec/message/611168891</stembedurl>Amezalpat, Tempest's lead candidate, has received both Orphan Drug and Fast Track designations from the FDA.&nbsp;TPST-1495, a dual EP2/EP4 antagonist, is also advancing toward a Phase 2 trial in familial adenomatous polyposis (FAP) with NCI support.<a href="https://stocktwits.com/symbol/TPST">Tempest Therapeutics stock</a> has lost over 34% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger

CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study. 

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Tempest Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

Current Price	$2.33
Prev Close	$2.42
Open	$2.34
Dividend Yield	0.00%
50-Day Moving Average	$2.86
Beta	2.15
Avg. Volume	87,184.70
PE Ratio	-0.24

52-Week High	$12.37
52-Week Low	$2.17
Market Capitalization	$32.62M
EPS (Annual)	-$19.50
Price to Book	1.69
Revenue Per Employee	$0.00

TPST
Tempest Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TPST News

TPSTTempest Therapeutics Inc